Molecular characteristics of anaplastic astrocytomas and isolation of molecular subgroups of their IDH1 mutant forms using in silico analysis
| Autor: | P. V. Nikitin, A. Yu. Belyaev, M. V. Ryzhov |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Бюллетень сибирской медицины, Vol 19, Iss 3, Pp 177-187 (2020) |
| Druh dokumentu: | article |
| ISSN: | 1682-0363 1819-3684 |
| DOI: | 10.20538/1682-0363-2020-3-177-187 |
| Popis: | Aim. The problem of anaplastic astrocytomas is quite relevant today. The WHO classification distinguishes IDH1/IDH2 mutant anaplastic astrocytomas, anaplastic astrocytomas without IDH1/IDH2 mutations, and anaplastic astrocytomas not otherwise specified. The aim of this work was to cluster IDH1-mutant anaplastic astrocytomas based on their cytogenetic profile to select prognostically significant molecular subgroups, which can have both clinical and fundamental scientific value.Materials and methods. In this work, we performed a cluster analysis of anaplastic astrocytomas according to their cytogenetic profiles based on available genetic databases of tumors and large cohort studies, as well as a comparison of Kaplan – Meyer survival curves for various molecular subgroups of patients.Results. We studied the main genetic features of the inter-tumor heterogeneity of anaplastic astrocytomas and distinguished seven molecular subgroups based on the cytogenetic profile: embryo-like, inflammatory-like, deletion, matrix, cyclin, GATA3-dependent and tyrosine kinase. Moreover, each of these subgroups has not only distinctive molecular characteristics, but also important clinical features.Conclusion. A detailed study of the molecular properties of anaplastic astrocytomas will not only optimize the process for predicting treatment outcomes, but also create innovative formats for targeted therapy within the framework of the concept of personalized medicine. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|